Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma

Metastatic disease from uveal melanoma occurs in almost 50% of patients suffering from this ocular tumour, with median survival from development of symptoms being around 1 year. In contrast to cutaneous melanoma, kinase inhibitors and immune checkpoint inhibitors are usually ineffective in patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Damato, Bertil E., Dukes, Joseph, Goodall, Howard, Carvajal, Richard D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6679206/
https://www.ncbi.nlm.nih.gov/pubmed/31336704
http://dx.doi.org/10.3390/cancers11070971

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6679206/
https://www.ncbi.nlm.nih.gov/pubmed/31336704
http://dx.doi.org/10.3390/cancers11070971

Ejemplares similares